Description
SP Equipoise (Boldenona-E) | 1 ampoule / ml – 200 mg / ml | Boldenone SP Labs
CHECK FOR AUTHENTICITY (ORIGINAL)
We guarantee quality!
STEROID PROFILE
- Androgenic index 50,
- Anabolic index 100,
- Estrogenic activity is low
- Progestogenic activity is very low
- Half-life – 14 days
- Toxicity to the liver – no.
- The withdrawal period of the drug is 4-5 months
The first modification of this steroid was developed primarily for veterinary use. Many athletes prefer this particular steroid because it can be used to get a good amount of muscle.
The drug is a derivative of testosterone, which exhibits a strong anabolic and moderate androgenic effect. Moreover, this steroid has a prolonged action, which allows you to minimize the frequency of injections. Also, this steroid is not toxic to the liver.
EFFECT OF RECEPTION OF BOLDENONE (EQUIPOISE)
An athlete, taking this drug in strict accordance with the recommendations of a specialist, can get results such as:
- A set of quality muscles,
- increased appetite,
- Increasing levels of fitness and activity
- By stimulating the production of red blood cells, the transport of oxygen and other nutrients to the muscles improves.
Also, the drug helps to increase endurance, which makes it especially popular among athletes, track and field athletes, skiers, etc.
APPLICATION OF BOLDENONE (EQUIPOISE)
Experts recommend taking this steroid at least once a week. Thus, you can get the maximum efficiency from the course and maintain an even hormonal background. The drug is also allowed to be used by women. But, if the average weekly dosage for men ranges from 400 to 600 mg, then for women it will be no more than 50-150 mg per week. Usually the duration of the course of taking this drug is no more than 8-10 weeks.
It is also allowed to take the drug in combination with other steroids such as Trenbolone or Enanthate. Basically, additional drugs can increase the effect of gaining muscle mass. However, after side courses, experts recommend mandatory PCT.
Reviews
There are no reviews yet.